SAB Biotherapeutics Inc. – Filings and Transcripts

NASDAQ: SABS
Share price (11/6/26): $3.03
Market cap (11/6/26): $273 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/26 Q3

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

Prospectuses and Registrations Filter

Removal from listing

Prospectus supplement

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Kropotova Alexandra

Commodore Capital LP

Caligan Partners LP

Vivo Opportunity Fund Holdings, L.P.

Perceptive Advisors LLC

News Filter

BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

Shareholder Vote Results

Material Definitive Agreement, Financial Statements or Exhibits

BIO Presents Additional Clinical and Mechanistic Data From SAB-142 Phase 1 Trial in Adult Patients With Established Autoimmune Type 1 Diabetes at IDS 2026

Proxies Filter

Definitive proxy

Definitive proxy

Preliminary proxy

Definitive proxy

Definitive proxy

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness

Correspondence with the SEC